Both high expression of CBP and RFPL3 predicted a shorter overall survival time in patients with lung adenocarcinomas compared with those with dual low expression of these two proteins (P < 0.001, log-rank test; Figure 3C). This evidence concerns the gene RFPL3 and lung adenocarcinoma.